How to regulate stimulants? A practical guide

📜🔗LINK to the source

1. ANALYTICAL SUMMARY

Context, issues and audiences

The document starts from the observation of a massive and documented failure of the "war on drugs", which has neither reduced the use nor the production of stimulants, but has generated violence, over-criminalisation and large-scale human rights violations. It notes that the consumption of cocaine, amphetamines and MDMA is increasing globally and in the French-speaking space, with a rise in overdoses and increasingly concentrated and variable purity products, in a completely deregulated black market. The work distinguishes three main usage profiles – functional, recreational and addictive – and emphasises that stimulants are not solely "party" products, but permeate work, performance, sexuality, military, student and professional contexts. It addresses a wide range of stakeholders: public decision-makers, field workers, affected individuals, researchers and advocacy networks, particularly in the French-speaking world (Canada, Belgium, France, Switzerland). The French introduction highlights the transformation of the international context (UNGASS 2016, UN repositioning on health and human rights, debate on coca) and the necessity to consider the regulation of stimulants, which has so far been marginalised compared to cannabis and psychedelics.

Operational contributions for the field

The document proposes a clear regulatory framework, articulated in five graduated models (medical prescription, sale in specialised pharmacies, licences for on-site consumption, licences for off-site consumption, sale without a licence) allowing for the adjustment of the level of control to the specific risks of the products. It offers dedicated chapters on MDMA, amphetamines, and cocaine, which combine pharmacological data, uses, risks, and detailed regulatory scenarios (types of authorised products, locations, access controls, professional responsibilities). An entire chapter addresses public policy levers (taxation, state monopoly, marketing controls, licences, indicators) and the prioritisation of public health, social justice, and safety. The guide also devotes a large section to risk reduction specific to stimulants (smoking kits, sexual risk prevention, women’s interventions, consumption rooms, housing first, substitution, peer interventions, drug analysis, online interventions, therapeutics) with examples of best practices. Finally, it provides a framework for aligning national policies with UN conventions (treaty reform, 'respectful' non-compliance, new framework conventions) and for integrating sustainable development and fair trade issues in producing countries (case studies Guinea-Bissau, Colombia, Bolivia, peasant coca).

2. KEY POINTS OF THE DOCUMENT

1. The recognition of the failure of prohibition and its 'unintended consequences'

   The document systematically outlines the structural failure of drug prohibition: increased production, market diversification, violence, corruption, destabilisation of transit countries, links to other forms of crime, and human rights violations. It cites reports from the UNODC and UN bodies that recognise the ineffectiveness of punitive policies, and emphasises that stimulant markets are now established and growing, despite a strengthened prohibition framework. This factual basis serves as a political foundation to legitimise reflection on regulation rather than on repressive intensification, starting from chapter 1 "Why regulate stimulants?" (p.19–37).

2. Five models of graduated regulation of stimulants

   The conceptual core of the guide is based on five models of supply regulation: medical prescription, sale in specialised pharmacies, licences for on-site consumption ("on-sales"), licences for off-site consumption ("off-sales"), and unlicensed sale under general food regulation. Each model is illustrated by existing examples (TAO and prescribed heroin, Uruguayan pharmacies for cannabis, alcohol/tobacco licensing systems, coca coffee and tea) and adapted to stimulants, highlighting issues of training, age control, clinical or social monitoring, and prevention of diversion. This typology, located p.39–43, offers an immediately mobilisable tool for thinking about local or national scenarios, based on systems familiar to professionals (alcohol licences, pharmacies, medications).

3. A detailed analysis of stimulant use (functional, recreational, addictive)

   The document proposes an operational typology of usage motivations: functional (management of fatigue, professional or academic performance, military use, self-medication), recreational (pleasure, sociability, dance, sexuality) and addictive (compulsive use, concentrated preparations, rapid-release consumption methods). This reading nuances the homogeneous and moralistic view of stimulant use, allowing for the association of different risk profiles and the calibration of differentiated responses (policies, clinical, harm reduction). The text emphasizes that the majority of recreational uses are infrequent and contextualized, while the burden of morbidity is concentrated on sub-groups, according to a Pareto-type distribution, which questions uniform policies. This detailed analysis is found on pp. 43–47 for motivations, and is then revisited in the produced chapters (MDMA pp. 125–155; amphetamines pp. 169–183; cocaine pp. 213–233).

4. Produced chapters: MDMA, amphetamines, cocaine and specific regulatory models

   The work dedicates entire chapters to MDMA (p.125–162), to amphetamines (p.169–199, with BZP cases p.204), and to cocaine and coca products (p.213–266). Each chapter describes the history, effects, consumption habits, risks (acute and chronic), and then puts forward an adapted regulatory model: types of permitted products (powder, pills, less concentrated preparations, crack), modes of access (prescription, pharmacies, on/off licenses), purity controls, quantity limits, and associated risk reduction measures. For example, the MDMA section details consumption methods, effects, prevalences, and risks, and then discusses options for regulated distribution models to limit overdoses, purity variability, and counterfeit products. These chapters provide a technical working basis for stakeholders who wish to advocate for or design specific frameworks by substance, rather than indistinct global approaches.

5. Risk reduction and UN framework: articulating field, national policies, and international law

   Chapter 7 (Reducing risks related to stimulants, p.313–344) brings together a range of measures: safer smoking kits, sexual risk prevention, women-centred interventions, consumption rooms, housing first, substitution, peers, reception centres, drug analysis, online interventions, therapeutic interventions. It illustrates, through examples of good practices, how stimulant regulation can only be effective when articulated with risk reduction, care, and social inclusion policies. Chapter 8 (Navigating the UN drug control system, p.347–362) explains the options for treaty reform: single framework convention, amendment of existing conventions, withdrawal with conditional re-adherence, respectful non-compliance, inter se modification, which equips political and legal actors to consider the compatibility of regulation with international law. This set strengthens the operational credibility of the guide, linking field intervention, national regulation, and UN framework.

 5 models of drug supply regulation

1. Medical prescription: the substance is provided only under medical supervision, on prescription and within a care framework.

2. Specialised pharmacy: the substance is sold in a pharmacy or dedicated distribution point, with age control, dosage, and advice.

3. ‘On-sales’ licence: sales and consumption take place on-site in licensed venues (type bar/club regulated).

4. ‘Off-sales’ licence: sales occur in licensed retail outlets, but consumption takes place elsewhere (home, private spaces).

5. Sale without a licence: some low-risk preparations are sold freely, with only general quality and labelling rules.

3. ACTION PATHWAYS FOR LOCAL ACTORS

1. Build local advocacy based on the five regulatory models

   Local actors (local authorities, associations, professional networks) can use the typology of the five models (pp.39–43) to develop contextualised scenarios for the regulation of stimulants, starting from already known devices (pharmacies, alcohol licences, substitution programmes). A concrete use consists of organising workshops with elected officials, professionals, and concerned individuals to map existing devices (TAO, consumption rooms, harm reduction programmes) and project them into graduated regulatory models (prescription for certain populations, licensed sale for others, etc.). This approach allows for moving beyond the binary debate of "legalisation / prohibition" and advocating for combinations suited to the local socio-health context.

2. Strengthen and adapt harm reduction measures for stimulant users

   Chapter 7 (p.313–344) offers a detailed list of interventions: safe smoking kits, targeted HIV/STI prevention in stimulant use contexts, specific women interventions, consumption rooms, housing first programmes, stimulant substitution, peers, reception centres, drug analysis, online interventions, therapeutic devices. Local actors can use this to audit their systems: what services exist, for which audiences, what links are missing (for example, absence of smoking kits or women-oriented programmes). An operational avenue consists of creating, based on this typology, local action plans (for example, opening a drug analysis service linked to a festival, or integrating stimulant modules into consumption rooms), prioritising high-impact and quickly feasible interventions.

3. Involve the affected individuals in the co-construction of local policies

   The French introduction emphasises the co-construction of regulatory policies with the individuals directly affected, recognising their practical expertise and fundamental rights. Local actors can translate this principle into concrete measures: steering committees including users, community consultations on access modalities (hours, locations, conditions), involvement of peers in the design and evaluation of services (drug analysis, online interventions, consumption rooms). The text reminds us that regulation should not reproduce the injustices of prohibition and must explicitly include the most affected communities (p.35–38), which advocates for established participatory mechanisms, not just ad hoc ones.

4. Use the UN framework as a lever to secure local innovation

   Chapter 8 (p.347–362) explains several strategies for reform or partial circumvention of UN conventions, such as amending conventions, respectful non-compliance, or negotiating a new framework convention. Local actors can use this to argue that certain innovations (drug analysis, consumption rooms, regulated distribution programmes) can fit within interpretative margins or ongoing developments in international law. Specifically, this allows for the preparation of framing notes for elected officials or administrations, showing that local reforms are not necessarily in outright conflict with international commitments, but are part of a global movement to reposition health and human rights.

5. Integrate the dimensions of sustainable development and fair trade into international partnerships

   Chapter 6 (Sustainable Development and Fair Regulation, p.269–307) offers case studies (Guinea-Bissau, Colombia, Bolivia, fair trade) and advocates for a shift from a ‘shared responsibility’ focused on eradication to a ‘shared responsibility’ for fair regulation. Decentralised cooperation actors, NGOs, and foundations can rely on these analyses to co-construct partnerships with producer organisations (coca, other crops) aimed at regulated supply chains, fair trade-type certifications, and genuinely negotiated substitution programmes with communities. This perspective allows for linking local public health policies to global issues of economic justice, moving beyond the sole logic of repressing illicit crops in the Global South.

4. ADDITIONAL REFERENCES

🔍➕ For more information, see the articles referenced by "Health Practices" on the topic of addictions  ➡️🔗 https://pratiquesensante.odoo.com/4-5-les-addictions

5. FREQUENTLY ASKED QUESTIONS (FAQ)

1. Why does the document state that prohibition has failed?

   The document relies on reports from the UNODC and various UN agencies that note a continuous increase in production, diversification of markets, and links to other forms of crime, despite decades of repressive policies. It shows that prohibition has not prevented the use of stimulants but has generated "unintended consequences": violence, corruption, destabilisation of countries, human rights violations, over-criminalisation of consumers. Reference: chapter 1 "Why regulate stimulants?" (p.21–28).

2. What are the main reasons put forward for regulating stimulants?

   The text emphasises that stimulant markets already exist, with increasingly concentrated and variable purity products, without health control, and that the most vulnerable populations bear the consequences. It advocates for legal regulation as a means to reduce the grip of organised crime, improve public safety, and establish more effective prevention and risk reduction mechanisms, while respecting individual autonomy. Reference: p.21–29.

3. What does the typology of the five models of regulation consist of and how can it be used in practice?

   The five models range from medical prescription to unlicensed sale, including sale in specialised pharmacies and licences for on-site or off-site consumption. Each model is described with its safeguards (age controls, training of professionals, conditions of sale, product regulation) and can serve as a basis for designing local scenarios adapted to the risk level of each stimulant and the legal context. Reference: section "Five Models of Regulation" (p.39–43).

4. How does the document take into account the different types of stimulant use?

   The guide distinguishes functional use (performance, alertness), recreational use (pleasure, sociability), and addictive use (compulsive consumption, highly concentrated products, risky modes of administration). This typology allows for tailored responses: interventions on working conditions and performance for functional use, prevention and risk reduction for festive contexts, care and intensive interventions (including substitution and housing first) for addictive uses. Reference: section "Regulation and Motivations for Stimulant Consumption" (p.43–47).

5. Does the document propose concrete risk reduction tools for stimulants?

   Yes, chapter 7 presents a range of tools: safer smoking kits, sexual risk prevention programmes, women-centred interventions, consumption rooms, housing first, substitution, peer interventions, drop-in centres, drug analysis, online interventions, and therapeutic approaches. Each tool is illustrated with examples of good practices, allowing field services to draw inspiration or advocate for their implementation. Reference: "Risk Reduction in Relation to Stimulants" (p.313–344).

6. How does the document articulate the regulation of stimulants and the international legal framework (UN)?

   Chapter 8 clarifies the options for reform or adjustment of international conventions: new framework convention, amendments to existing treaties, withdrawal and re-adherence, respectful non-compliance, inter se mechanisms. It shows that states can, while respecting their international obligations, experiment with legal regulations of stimulants, particularly by invoking public health, human rights, and sustainable development objectives. Reference: "Navigating the UN drug control system" (p.347–362).

7. Does the document provide guidance for integrating social justice and sustainable development into regulation?

   Yes, chapter 6 addresses the transition to regulated markets in connection with producing countries, detailing case studies (Guinea-Bissau, Colombia, Bolivia) and discussing fair trade models and "shared responsibility" oriented towards equitable regulation rather than eradication. It emphasizes the need to rectify historical injustices, involve producing communities, and design policies that combine public health, social justice, and sustainable development. Reference: "Sustainable development and equitable regulation" (p.269–307).

6. REWRITING IN EASY TO READ LANGUAGE 

Analytical summary – Easy to Read Version

1. Context and issues

• Many people use stimulant drugs, such as cocaine, amphetamines, and MDMA.

• These drugs are often very strong and sold uncontrolled, on illegal markets.

• Current laws mainly punish people who consume and small sellers.

• These laws do not really prevent use, but create more violence and injustices.

• The book speaks to policymakers, professionals, volunteers, and those affected.

• It aims to help build fairer rules for these drugs.

2. Operational Contributions

• The book offers several ways to control these drugs, with more or fewer rules.

• It describes five models: prescription, pharmacies, licensed venues, takeaway, sales with simple rules.

• It explains for each product (MDMA, amphetamines, cocaine) the effects, risks, and possible solutions.

• It provides concrete ideas to reduce risks: equipment, rooms, housing, care, peer actions.

• It also shows how to adapt international and national laws to protect health and rights.

• Professionals can use this book to build local projects and advocacy.

Key Points – Easy-to-Read Version

1. Prohibition does not work

• Strongly banning drugs has not eliminated use.

• It has created more violence, imprisonment, and suffering.

1. Five models of regulation

• The book proposes five levels of control, depending on the risk.

• One can choose a different model for each drug.

1. Three types of use

• People use to work, to have fun, or because they are dependent.

• Each use has different risks and requires an appropriate response.

1. Chapters for each product

• There is a chapter on MDMA, one on amphetamines, one on cocaine.

• It includes the history, effects, risks, and ideas for regulation.

1. Harm reduction and human rights

• The book emphasises harm reduction, rights, social justice, and sustainable development.

• It offers concrete examples and ideas for changing the laws.

7. CROSS-ANALYSIS — VALUES OF HEALTH PRACTICES

• Literacy: The document provides clear definitions (prohibition, legalisation, regulation, decriminalisation) and a chapter "Notes on Translation", which facilitates understanding for diverse audiences, but remains largely written in expert language.

• Empowerment: It strongly values the lived expertise of the individuals concerned and recommends that regulatory policies be co-constructed with them, recognising their rights and knowledge.

• Participation: The French introduction emphasises co-construction with communities, and the document proposes models where peers play a central role in local interventions and the governance of systems.

• Community health: The collective dimension is present through the chapters on markets, producing communities, community harm reduction systems, and housing first.

• Ethics: The text identifies the biases and injustices of prohibition (discrimination, over-criminalisation of marginalised groups) and calls for regulatory models centred on equity, social justice, and human rights.

• Human rights: The document explicitly anchors the reform of drug policies in respect for human rights, dignity, social justice and sustainable development, citing recent UN repositionings.

• Intersectorality: It proposes linkages between health, justice, development, agriculture, fair trade and the UN framework, particularly in the chapter on sustainable development and fair regulation.

• Partnership: The French-speaking edition comes from a transnational partnership (AIDQ, féda bxl, Fédération Addiction, GREA), and the text promotes formalised collaboration models between institutions and communities.

• Fight against discrimination: The document denounces the stigma, criminalisation and violations of rights suffered by people who consume, and promotes non-judgmental, inclusive approaches and respect for diverse usage profiles.

8. EVALUATION OF THE RELIABILITY OF THE RESOURCE

Scientific relevance

The document relies on a significant bibliographic basis: UNODC reports (World Drug Report), reports from the United Nations Commission on Narcotic Drugs, scientific publications on harm reduction, clinical trials (for example on MDMA), work from the EMCDDA/EUDA, reports from international NGOs (Open Society Foundations, Global Commission on Drug Policy). It cites sources updated until at least 2020 for the original version, and the French introduction incorporates references up to 2025 (UN review, Harm Reduction International conference in Bogotá). The methodology is primarily of the 'policy paper' type: critical analysis of prohibition, review of existing data, proposal of normative models, but not a clinical trial or meta-analysis; nevertheless, the references are coherent, multidisciplinary, and aligned with public health and harm reduction standards.

Operational relevance

The guide has a strong operational value: it translates analyses into concrete models (five levels of regulation), product scenarios (MDMA, amphetamines, cocaine), harm reduction tools, and treaty reform options. It is clearly aimed at professionals and decision-makers who wish to design or advocate for regulatory policies, with descriptions of political levers (state monopoly, taxation, licenses, evaluation indicators) and practical recommendations. The proposals are contextualised (cannabis in Uruguay, social clubs, European examples) and recognise economic, legal, and political constraints, which enhances feasibility and usability on the ground.

​